Sarepta Therapeutics,, Inc. (SRPT) Debt by Year
Sarepta Therapeutics,, Inc. carried $829.0M in long-term debt against $801.3M in cash and equivalents at the end of fiscal year 2025. This represents a decrease of 27.1% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Sarepta Therapeutics,, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
SRPT Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $829.0M-27.1% | $1.1B-8.1% | $1.2B-19.8% | $1.5B+174.0% | $563.7M | N/A | N/A | $420.6M-2.4% | $431.1M+2339.7% | $17.7M-34.2% | $26.8M+1718.3% | $1.5M-6.3% | $1.6M-5.5% | $1.7M-5.1% | $1.8M |
| Cash & Equivalents | $801.3M-27.4% | $1.1B+157.5% | $428.4M-55.7% | $966.8M-54.3% | $2.1B+40.8% | $1.5B+79.9% | $835.1M+125.2% | $370.8M-38.2% | $599.7M+389.9% | $122.4M+52.4% | $80.3M+9.2% | $73.6M-71.4% | $257.0M+36.9% | $187.7M+370.3% | $39.9M |
SRPT Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K | Q2'2410-K | Q1'2410-K | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $847.6M | $838.2M | $829.0M-27.1% | $140.5M-88.6% | N/A | N/A | $1.1B-8.1% | $1.2B-0.7% | $1.2B-0.7% | $1.2B+0.4% | $1.2B-19.8% | $1.2B-19.8% |
| Cash & Equivalents | $571.1M+11.9% | $464.4M+92.8% | $801.3M-27.4% | $613.1M+209.9% | $510.6M+33.1% | $240.9M-43.6% | $1.1B+157.5% | $197.9M-63.5% | $383.6M-55.0% | $427.3M-51.0% | $428.4M-55.7% | $541.9M-47.8% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Sarepta Therapeutics,, Inc. financials
Frequently Asked Questions
What was Sarepta Therapeutics,, Inc.'s long-term debt in fiscal year 2025?
Sarepta Therapeutics,, Inc. carried $829.0M in long-term debt against $801.3M in cash and equivalents at the end of fiscal year 2025.
How fast is Sarepta Therapeutics,, Inc.'s long-term debt growing?
Sarepta Therapeutics,, Inc. (SRPT) long-term debt fell by 27.1% year over year, from $1.1B to $829.0M in fiscal year 2025.
How has Sarepta Therapeutics,, Inc.'s long-term debt changed over the years?
Across the 15 fiscal years this page covers, Sarepta Therapeutics,, Inc. (SRPT) long-term debt went from $1.8M in fiscal year 2011 to $829.0M in fiscal year 2025.
What was Sarepta Therapeutics,, Inc.'s long-term debt in the most recent quarter?
Sarepta Therapeutics,, Inc. (SRPT) reported $847.6M in long-term debt in Q2 2026.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Sarepta Therapeutics,, Inc. (SRPT) reported on that line in every period on record.